Related references
Note: Only part of the references are listed.Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
Giacomo Allegrini et al.
ANGIOGENESIS (2012)
Metronomic Activity of CD44-Targeted Hyaluronic Acid-Paclitaxel in Ovarian Carcinoma
Sun Joo Lee et al.
CLINICAL CANCER RESEARCH (2012)
Paclitaxel in Cancer Treatment: Perspectives and Prospects of its Delivery Challenges
Somnath Singh et al.
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS (2012)
Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity
Liang Liang et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Age and Comorbidity Considerations Related to Radiotherapy and Chemotherapy Administration
George Rodrigues et al.
SEMINARS IN RADIATION ONCOLOGY (2012)
Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies
Katiuscia Bonezzi et al.
NEOPLASIA (2012)
Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
Yutaka Yamamoto et al.
ONCOTARGETS AND THERAPY (2011)
Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide
Urban Emmenegger et al.
NEOPLASIA (2011)
Antiangiogenic Activity of Sterically Stabilized Liposomes Containing Paclitaxel (SSL-PTX): In Vitro and In Vivo
Yue Huang et al.
AAPS PHARMSCITECH (2010)
Low-Dose Metronomic Paclitaxel Chemotherapy Suppresses Breast Tumors and Metastases in Mice
Hongchi Jiang et al.
CANCER INVESTIGATION (2010)
Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis
Chi-An Chen et al.
MOLECULAR THERAPY (2010)
Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts
Mu Zhan et al.
ANTI-CANCER DRUGS (2009)
Antivascular Actions of Microtubule-Binding Drugs
Edward L. Schwartz
CLINICAL CANCER RESEARCH (2009)
Paclitaxel downregulates tissue factor in cancer and host tumour-associated cells
Emanuela Napoleone et al.
EUROPEAN JOURNAL OF CANCER (2009)
Functionalized nanospheres loaded with anti-angiogenic drugs: Cellular uptake and angiosuppressive efficacy
Taha Hammady et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2009)
Effect of Low-Dose Paclitaxel and Docetaxel on Endothelial Progenitor Cells
Mariko Muta et al.
ONCOLOGY (2009)
Nanoparticle Albumin-Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery
Qiang Fu et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2009)
Active targeting schemes for nanoparticle systems in cancer therapeutics
James D. Byrne et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
A Novel Assay to Assess the Effectiveness of Antiangiogenic Drugs in Human Breast Cancer
John M. Lyons et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
G. Allegrini et al.
BRITISH JOURNAL OF CANCER (2008)
Targeting Microtubules to inhibit angiogenesis and disrupt tumour vasculature: Implications for cancer treatment
Eddy Pasquier et al.
CURRENT CANCER DRUG TARGETS (2007)
Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton
Marcel N. A. Bijman et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin
JE Damber et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation
Janice Murtagh et al.
CANCER RESEARCH (2006)
In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors
Joanna M. Koziara et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Microtubule-targeting agents in angiogenesis:: Where do we stand?
Eddy Pasquier et al.
DRUG RESISTANCE UPDATES (2006)
Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice
SR Olsen
BIOMEDICINE & PHARMACOTHERAPY (2005)
Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells
E Pasquier et al.
CANCER RESEARCH (2005)
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox-2 inhibition
JR Merchan et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals:: a quantitative study
B Lennernäs et al.
APMIS (2004)
Taxane-mediated antiangiogenesis in vitro:: Influence of formulation vehicles and binding proteins
SSW Ng et al.
CANCER RESEARCH (2004)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
Angiogenesis gene expression profiling in xenograft models to study cellular interactions
VLJL Thijssen et al.
EXPERIMENTAL CELL RESEARCH (2004)
Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?
D Lau et al.
ANTI-CANCER DRUGS (2004)
Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line
K Hata et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
The immunophannacology of paclitaxel (Taxol®) docetaxel (Taxotere®), and related agents
FA Fitzpatrick et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2003)
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
G Bocci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Taxol inhibits melanoma metastases through apoptosis induction, angiogenesis inhibition, and restoration of E-cadherin and nm23 expression
F Wang et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2003)
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)
DS Grant et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Angiogenesis inhibition with TNP-470, 2-methoxyestradiol, and paclitaxel in experimental pancreatic carcinoma
E Ryschich et al.
PANCREAS (2003)
Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a humanized SCID mouse model
R Kunstfeld et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
Anti-invasion and anti-angiogenesis effect of taxol and camptothecin on melanoma cells
F Wang et al.
JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH (2003)
Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly
JY Wang et al.
ANTI-CANCER DRUGS (2003)
Docetaxel versus paclitaxel for antiangiogenesis
A Vacca et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2002)
Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma
H Myoung et al.
CANCER LETTERS (2001)
'Accidental' anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples
RS Kerbel et al.
EUROPEAN JOURNAL OF CANCER (2000)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
G Klement et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
